Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults undergoing liver and/or kidney transplantation~Exclusion Criteria:~* transplant patients with contraindications to tacrolimus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of Care Tacrolimus Drug Dosing
- Phenotypic Precision Medicine (PPM) (Type: EXPERIMENTAL): PPM-based Computation Assisted Drug Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).